Oppenheimer & Co. Inc. Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN

Oppenheimer & Co. Inc. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 23,714 shares of the biopharmaceutical company’s stock after purchasing an additional 1,597 shares during the period. Oppenheimer & Co. Inc.’s holdings in Regeneron Pharmaceuticals were worth $13,334,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Salomon & Ludwin LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $31,000. Traub Capital Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $38,000. E Fund Management Hong Kong Co. Ltd. grew its stake in Regeneron Pharmaceuticals by 87.5% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 35 shares during the last quarter. Finally, Berbice Capital Management LLC increased its position in Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 60 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $780.28 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The company has a 50 day moving average price of $757.89 and a 200-day moving average price of $660.34. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The firm has a market cap of $82.01 billion, a price-to-earnings ratio of 18.77, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm’s revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the business earned $12.07 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 8.47%.

Analysts Set New Price Targets

Several brokerages have weighed in on REGN. HSBC started coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 price target for the company. Cantor Fitzgerald lifted their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Citigroup upped their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Finally, UBS Group boosted their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $793.81.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.